1. Pink Sheet
  2. >>Geography
  3. >>Europe

Game-Changing EU-Level HTA Regs Must Allow For Lessons To Be Learned

 
• By Francesca Bruce

EU joint clinicals assessments introduced under the HTA Regulation have now gone live for cancer medicines and advanced therapies.

Paper
Joint clinical assessments mean big change for Europe's pricing and reimbursement landscape
Key Takeaways
  • EU-level joint clinical assessments (JCAs), which are similar to member-state level relative effectiveness assessments, are now applicable for new oncology medicines and advanced therapies.

The landmark Health Technology Assessment (HTA) Regulation and the EU-level joint clinical assessments (JCAs) that represent a huge shift in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

Belgium Competition Authority Tackles Reimbursement Barriers For Combination Drugs

 
• By Francesca Bruce

The Belgian Competition Authority has set out guidance on how pharmaceutical companies can share information on combination therapies when seeking their reimbursement.

EMA Backs 14 New Drugs, Confirms Atropine Rejection For Myopia

 
• By Vibha Sharma

The European Medicines Agency’s human medicines committee has recommended 14 new drugs for marketing approval, including treatments for RSV, menopause, diabetes, and generalized myasthenia gravis.

Speed, Reach And Impact: New Metrics To Drive EU Clinical Trials Reform

 
• By Vibha Sharma

Clinical trials in the EU will be measured against new benchmarks from 2026 to identify how the bloc’s clinical research environment compares with that of other regions, and to identify areas for improvement.

EU-Level Efforts To Mitigate Drug Shortages Unsuccessful, Audit Reveals

 
• By Eliza Slawther

Actions taken by the European Commission and European Medicines Agency to tackle critical shortages of medicines have not succeeded in practice and further systemic improvements are required to address supply issues, a report from the European Court of Auditors has found.

More from Market Access

Japan Expands Essential Drug List For Economic Security

 
• By Lisa Takagi

Japan's government has already allocated more than $400m to repatriate manufacturing of important drugs and continues to provide support as it expands a list of "national security" drugs.

Do Policy, Clinical Data, Ocaliva Exit Lend Zydus Helping Hands?

 
• By Vibha Ravi

Intercept’s Ocaliva withdrawal in the US places the spotlight on emerging PBC candidates like Zydus’s saroglitazar, a PPAR agonist that beat both Gilead’s Livdelzi and Ipsen’s Iqirvo on biochemical response in topline results. Will the withdrawal and policy developments boost Zydus’s prospects?

More Vaccines At Risk At Upcoming ACIP Meeting As New Panel Members Join

 
• By Sarah Karlin-Smith

The ACIP put hepatitis B and MMRV vaccines on its agenda, despite having no new reason to relitigate the products, worrying public health experts that more anti-vaccine moves are coming.